Aim. The efficacy of the short hydration regimen was reported in chemotherapy containing intermediate- to high-dose @entity900 , and the use of outpatient chemotherapy containing @entity900 with short hydration has been widespread in recent years. Methods. We compared @entity1 with @entity356 , @entity2 , and @entity5 who received outpatient chemotherapy containing @entity900 (>= 60   mg/m(2)/cycle) with the short hydration regimen since April 2012 (n = 13) with those who received hospital chemotherapy with continuous hydration between April 2011 and March 2013 (n = 17) in our hospital. Results. Grade 2 or higher @entity810 occurred in 2 @entity1 in the continuous hydration group and in no @entity1 in the short hydration group; 1 @entity1 discontinued treatment on account of nephrotoxicity. There was no difference between the 2 groups in maximum creatinine increment and maximum clearance decrement. Relative dose intensity in the short hydration group was higher than that in the continuous hydration group (89.5% versus 80.3%; P < 0.01). Conclusions. The short hydration regimen in outpatient chemotherapy containing intermediate- to high-dose @entity900 is as safe as the continuous hydration regimen and increased the efficacy of chemotherapy.

Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['urothelial cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity810 :: ('MESH:D058186', 'Disease') :: ['acute kidney injury'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancer']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
